Cargando…
Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist Fenfluramine
Dravet syndrome (DS) is one of the most pharmacoresistant and devastating forms of childhood epilepsy syndromes. Distinct de novo mutations in the SCN1A gene are responsible for over 80% of DS cases. While DS is largely resistant to treatment with existing anti-epileptic drugs, promising results hav...
Autores principales: | Zhang, Yifan, Kecskés, Angéla, Copmans, Daniëlle, Langlois, Mélanie, Crawford, Alexander D., Ceulemans, Berten, Lagae, Lieven, de Witte, Peter A. M., Esguerra, Camila V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428833/ https://www.ncbi.nlm.nih.gov/pubmed/25965391 http://dx.doi.org/10.1371/journal.pone.0125898 |
Ejemplares similares
-
Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome
por: Li, Jing, et al.
Publicado: (2021) -
Fenfluramine: New Treatment for Seizures in Dravet Syndrome
por: Pierce, Joanna Garcia, et al.
Publicado: (2020) -
Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish
por: Sourbron, Jo, et al.
Publicado: (2017) -
Low‐dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients
por: Schoonjans, A., et al.
Publicado: (2016) -
Treatment of Focal-Onset Seizures in Children: Should This Be More Etiology-Driven?
por: Aeby, Alec, et al.
Publicado: (2022)